Key clinical point: Secukinumab is safe and effective in both the 150 mg and 300 mg doses for treating psoriasis.
Major finding: There were no significant differences in 150 mg versus 300 mg of secukinumab for the risk of “any adverse event, serious adverse events, and adverse events leading to drug discontinuation.”
Study details: Seven studies from multiple databases were used to compare the adverse events of 150 mg versus 300 mg of secukinumab for treating plaque psoriasis in 2,361 patients.
Zhang L, et al. Medicine (Baltimore). 2019 Jan;98(2):e14042. doi: 10.1097/MD.0000000000014042.